ACY-241 + ipilimumab + nivolumab

This is a **three-drug combination therapy** consisting of ACY-241 (citarinostat), ipilimumab, and nivolumab. - **ACY-241 (citarinostat)** is a selective histone deacetylase 6 (HDAC6) inhibitor that exerts immunomodulatory effects, likely enhancing immune system recognition of tumor cells by increasing histone and tubulin acetylation and promoting tumor-infiltrating cytotoxic T cells. - **Nivolumab** is a monoclonal antibody checkpoint inhibitor targeting programmed cell death protein 1 (PD-1), blocking its interaction with PD-L1/PD-L2, thereby reviving T-cell–mediated antitumor responses. - **Ipilimumab** is a monoclonal antibody checkpoint inhibitor that targets cytotoxic T-lymphocyte–associated protein 4 (CTLA-4), enhancing T-cell activation and proliferation. This combination is being investigated in clinical trials for patients with advanced melanoma as well as for other advanced solid tumors, aiming to enhance antitumor immunity through simultaneous epigenetic modulation and dual immune checkpoint blockade[1][5].

Other names

ACY-241 + ipilimumab + nivolumabcitarinostat + ipilimumab + nivolumab